The natural history of recurrent hepatitis C and what influences this

Liver Transplantation

Volumn 14, Issue SUPPL. 2, 2008, Pages

  Gane, Edward J ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTASIS; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; PATHOPHYSIOLOGY; RECURRENT DISEASE; REOPERATION; REVIEW; RISK FACTOR; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; CHOLESTASIS; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RECURRENCE; REOPERATION; RISK FACTORS;

EID: 58849128803     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21646     Document Type: Article

References (111)

1. Shepard C, Finelli L, Alter M. Global epidemiology of hepatitis C infection. Lancet Infect Dis 2005;5:558-567.
2. Australian Department of Health and Ageing. Estimates and projections of the hepatitis C virus epidemic in Australia 2006. Available at: http://www.health.gov.au/ internet/main/publishing.nsf/content/phd-hepc- estimates-project-06-l. Accessed August 2008.
3. CDC. Compressed mortality file. Available at: http:// wonder.cdc.gov/controller. Accessed June 2008.
4. National Health and Nutrition Examination Surveys 1988-2006. Available at: http://www.cdc.gov/nchs/ about/major/nhanes. Accessed June 2008.
5. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. Prevalence of HCV infection in the United States. Ann Int Med 2006;144:705-714.
6. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in HCV-related mortality in USA. Hepatology 2008;47:1128-1135.
7. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. HCV and increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-1380.
8. Davis G, Albright J, Cook S. Projecting future complications of chronic hepatitis C in United States. Liver Transpl 2003;9:331-338.
9. SRTR data 1990 to 2007. Available at: http://www. ustransplant.org/csr/ current/csrdefault.aspx. Accessed June 2008.
10. Kim W. The burden of hepatitis C in the Unites States. Hepatology 2002;36(SUPPL. 1):S30-S34.
11. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C kinetics during and immediately after transplantation. Hepatology 2002;35:680-687.
12. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262.
13. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus. Liver Transpl 2000; 6:44-53.
14. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:821-827.
15. Saraf N, Fiel MI, Deboccardo G, Emre S, Schiano TD. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl 2007;13:913-917.
16. Duvoux C, Pawlotsky J-M, Cherqui D, van Nhieu JT, Metreau J-M, Fagniez P-L, et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. Transplantation 1995;60:457-461.
17. DiMartino V, Saurini F, Samuel D, Gigou M, Reynes M, Dussaix E, et al. Longitudinal study of intra-hepatic HCV replication after liver transplantation. Hepatology 1997; 26:1343-1350.
18. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCV-infected liver. Liver Transpl 2002;8:10-20.
19. Gane E, Naoumov N, Qian K, Mondelli M, Maertens G, Lau J, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
20. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens H-P, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996;24:1351-1354.
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-332.
22. Prieto M, Berenguer M, Rayón JM, Córdoba J, Argü ello L, Carrasco D, et al. High incidence of allograft cirrhosis in HCV genotype 1b following transplantation. Hepatology 1999;29:250-256.
23. Berenguer M, Rayón JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, et al. Are posttransplantation protocol liver biopsies useful in the long-term? Liver Transpl 2001;7:790-796.
24. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent HCV following liver transplantation. Liver Transpl 2007;13:975-983.
25. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
26. Slapak G, Portmann B, Gane E, Devlin J, Calne R, Williams R. Graft and systemic disease in long term survivors of liver transplantation. Hepatology 1997;25:195-202.
27. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
28. Feray C, Caccamo L, Alexander G, and the EUROHEP group. HCV and liver transplantation: preliminary results of a European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
29. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. Association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
30. Sánchez-Fueyo A, Restrepo JC, Quintó L, Bruguera M, Grande L, Sánchez-Tapias JM, et al. Impact of recurrence of HCV infection after liver transplantation on the long-term viability of the graft. Transplantation 2002;73: 56-63.
31. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
32. Wali M, Harrison R, Gow P, Mutimer D. Advancing donor age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
33. Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, et al. All liver transplant recipients benefit from a protocol 10-year biopsy. Hepatology 2003;37:1293-1301.
34. Belli L, Burroughs A, Burra P. Liver transplantation for HCV-cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long-term retrospective study. Liver Transpl 2007;13:733-740.
35. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
36. Baiocchi L, Angelico M, Petrolati A, Perrone L, Palmieri G, Battista S, et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV-liver disease. Am J Transplant 2008;8:673-678.
37. Alter H, Seef L. Recovery, persistence and sequelae in hepatitis C infection. Semin Liver Dis 2000;20:17-35.
38. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hü rter D, et al. Prognosis of chronic hepatitis C. Hepatology 1998;28:1687-1695.
39. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
40. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
41. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C. Gastroenterology 1997;112:463-472.
42. Zekry A, Bishop G, Bowen D et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002;8:292-301.
43. Barton J, Rosen H. Retransplantation for HCV: survey of practice patterns in the United States. Clin Gastroenterol Hepatol 2005;3:700-704.
44. Rosen H, Martin P. HCV infection in patients undergoing retransplantation. Transplantation 1998;66:1612-1616.
45. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. HCV is a risk factor for death after liver retransplantation. Liver Transpl 2005;11:434-440.
46. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, et al. Retransplantation for HCV: results of a US multicentre retransplant study. Liver Transpl 2007; 12:1246-1253.
47. Ghabril M, Dickson RC, Machicao VI, Aranda-Michel J, Keaveny A, Rosser B, et al. Liver retransplantation of patients with HCV infection is associate with acceptable patient and graft survival. Liver Transpl 2007;13:1717-1727.
48. Ghabril M, Dickson R, Wiesner R. Improving outcomes in retransplantation: an analysis of trends and the impact of HCV infection. Am J Transplant 2008;8:404-411.
49. Boker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-210.
50. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. Ten year experience of liver transplantation for HCV. Ann Surg 2001;234:384-394.
51. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcome of 3200 transplantations over 2 decades. A single centre experience. Ann Surg 2005;241:905-918.
52. Thuluvath P, Krok K, Segev D, Yoo H. Trends in posttransplant survival in patients with HCV between 1991 and 2001 in the United States. Liver Transpl 2007;13: 719-724.
53. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C. Liver Transpl 2006; 81:7-14.
54. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplant for HCV-associated liver cirrhosis: recipient predictors of outcomes in population with significant genotypes 3 and 4 distribution. Liver Transpl 2003;9:339-347.
55. Fasola C, Netto G, Onaca N, Thomas M, Sanchez E, Chinnakotla S, et al. A more severe HCV recurrence postliver transplant observed in recent years may be explained by use of lower dose corticosteroid maintenance protocols. Hepatology 2003;38:226A.
56. Gane EJ, Portmann BC, McCartney M, Heaton N, Rela M, Naoumov NV, Williams R. Hepatocellular carcinoma in patients undergoing liver transplantation for HCV-cirrhosis. Abstract presented at: American Association for the Study of Liver Diseases Single Topic Symposium 1997.
57. Moya A, Berenguer M, Aguilera V, Juan FS, Nicolás D, Pastor M, et al. Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl 2002;8:1020-1027.
58. Herrero JI, de la Peña A, Quiroga J, Sangro B, Garcia N, Sola I, et al. Risk factors of recurrence of HCV after liver transplantation. Liver Transpl 1998;4:265-270.
59. Schwatz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S268-76.
60. Melum E, Friman S, Bjøro K, Rasmussen A, Isoniemi H, Gjertsen H, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol 2007;47:777-783.
61. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007;13:807-813.
62. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
63. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of HCV after liver transplantation. Hepatology 2000;32: 1125-1130.
64. Feray C, Gigou M, Samuel D, Okamoto H, Reynes M, David MF, et al. Influence of the genotypes on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1089-1097.
65. Alberti AB, Belli LS, Silini E, Bellati G, Asti M, d'Amico M, et al. HCV genotypes and severe hepatitis C recurrence after liver transplantation: report on 103 cases. Hepatology 1996;24:297A.
66. Villa E, Groffola A, Buttafoco P, Merighi A, Ferretti I, Trande P, et al. Long-term follow-up of hepatitis C virus (HCV) infection in liver transplant patients. Clin Transplant 1995;9:160-164.
67. Gayowski T, Singh N, Marino I, Vargas H, Wagener M, Wannstedt C, et al. HCV genotypes in liver transplant recipients. Transplantation 1997;64:422-426.
68. Zein NN, Rakela J, Poterucha JJ, Wiesner RH, Krom RA, Persing DH. HCV genotypes in liver transplant recipients: distribution and 1 year follow-up. Liver Transpl Surg 1995;1:354-357.
69. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
70. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, et al. HCV genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and ICAM-1 molecules. J Clin Invest 1995;95:2067-2075.
71. Nagayama R, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. Diagnostic and clinical implications of the different genotypes of HCV. J Clin Invest 1993;92:1529-1533.
72. Di Martino V, Brenot C, Samuel D, Saurini F, Paradis V, Reynés M, et al. Influence of liver HCV RNA and genotype on FAS-mediated apoptosis after liver transplantation for HCV. Transplantation 2000;70:1390-1396.
73. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
74. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22:30-35.
75. Lyra AC, Fan X, Lang DM. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002;123:1485-1493.
76. Doughty A, Painter D, McCaughan G. Posttransplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to HCV. J Hepatol 2000;32:126-134.
77. Schvoerer E, Soulier E, Royer C. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. JID 2007;196:528-536.
78. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.
79. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between CMV, HHV-6 and recurrence of HCV after liver transplantation. Am J Transplant 2002;2:461-466.
80. Humar A, Washburn K, Freeman R. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007;13:1422-1427.
81. Nebbia G, Mattes F, Cholongitas E. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007;13:130-135.
82. Belli LS, Burra P, Poli F, Battista Alberti A, Silini E, Zavaglia C, et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006;130: 695-702.
83. Langrehr J, Puhl G, Bahra M. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl 2006;12: 644-651.
84. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4- response to HCV and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926-932.
85. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of HCVspecific T-cell mediated immunity after liver transplantation. Hepatology 2005;41:72-81.
86. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56- innate lymphocyte populations associated with severity of HCV recurrence. Liver Transpl 2008;14:31-40.
87. Gane EJ, Maertens G, Ducatteeuw A, Qian KP, Lau JY, Jones H, et al. Antibodies to HCV envelope proteins correlate with HCV viraemia after liver transplantation. Transplantation 1999;67:78-84.
88. Gournay J, Ferrell LD, Roberts JP, Ascher NL, Wright TL, Lake JR. Cryoglobulinaemia after liver transplantation. Gastroenterology 1996;110:265-70.
89. Rahamimov R, Ilan Y, Eid A, Shouval D, Tur-Kaspa R. HCV-associated cryoglobulinaemia after liver transplantation. Transplantation 1995;60:1050.
90. Wiesner R, Demetris A, Seaberg E, Lake J, Zetterman R, Everhart J, et al. Acute hepatic allograft rejection: risk factors and impact on outcome. Hepatology 1998;28:638-645.
91. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
92. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
93. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery 1996;19:452-456.
94. Berenguer M, Prieto M, Cordoba J, Rayon J, Carrasco D, Olaso V, et al. Early development of chronic hepatitis in recurrent hepatitis C infection after liver transplantation- association with rejection. J Hepatol 1998;28:756-763.
95. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38:34-41.
96. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84:829-835.
97. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(-) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521-1531.
98. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
99. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47:793-798.
100. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005;11:386-389.
101. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
102. Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppressants on flaviviridae, including HCV. Transplantation 2004;77:562-567.
103. Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006;80:4510-4520.
104. Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, et al. Differential effects of tacrolimus and cyclosporine on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008;14:265-267.
105. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65:1044-1046.
106. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized-controlled trial of tacrolimus vs. microemulsified cyclosporine (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transpl 2007;7:137-141.
107. Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006;10:1464-1472.
108. Eghtesad B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005;11:1343-1352.
109. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-561.
110. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL. Timing and severity of initial HCV recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-1182.
111. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. Impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006;6:1922-1929.